Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315046 | 0.88 | LMNA (0.47) | ENPP2LMNATSHRHTTMGLL | |
| SCHEMBL315401 | 0.84 | MGLL (0.53) | ENPP2LMNATSHRHTTMGLL | |
| SCHEMBL316787 | 0.79 | MGLL (0.53) | LMNATSHRHTTMGLLMAPT | |
| SCHEMBL315951 | 0.76 | TP53 (0.61) | MGLLKMT2AMEN1TP53ALDH1A1 | |
| SCHEMBL315783 | 0.76 | TP53 (0.61) | MGLLPOLBKMT2AMEN1TP53 | |
| SCHEMBL316303 | 0.76 | PHGDH (0.54) | LMNATSHRHTTMGLLMAPT | |
| SCHEMBL314865 | 0.73 | TP53 (0.54) | LMNAMGLLTP53HSD11B1SMN1; SMN2 | |
| SCHEMBL314930 | 0.73 | TP53 (0.57) | LMNAMGLLTP53ALDH1A1HSD11B1 | |
| SCHEMBL12049735 | 0.72 | L3MBTL1 (0.41) | ENPP2HTTMAPTPOLBKMT2A | |
| SCHEMBL2709521 | 0.72 | SMN1; SMN2 (0.55) | HTTKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | ENPP2 292/4885LMNA 2443/4885TSHR 577/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | ENPP2 201/4885LMNA 1738/4885TSHR 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.